Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2019

View Archived Issues

New chemogenetics system could find clinical use

Kinase target as stroke target

Precision Biosciences initiates phase I/IIa study of PBCAR-0191 in relapsed/refractory B-ALL and NHL

CQDM awards grant to IMV and its collaborators to develop DPX-SurMAGE

Arch Biopartners receives approval for phase I study of Metablok in Australia

Transcription factor may be colitis immunotherapy target

Millendo Therapeutics initiates pivotal phase IIb/III ZEPHYR study of livoletide

Phase II data presented for MS-1819-SD recombinant lipase

IMP-761 inhibits antigen-specific T-cell-mediated immune responses in vitro and in vivo

Positive topline results presented from pivotal phase III EMPOWUR study of vibegron

OBE-022 demonstrates promising safety and PK in the first part of the PROLONG study

Trial supports uninterrupted edoxaban for atrial fibrillation undergoing catheter ablation

FDA places partial clinical hold on venetoclax trials in multiple myeloma

ICT completes pre-IND meeting with FDA for CAR-T candidate ICTCAR-014

Newave Pharmaceutical discloses new Bcl-2 inhibitors

Phase II trial begins in Taiwan with TJ-202 for relapsed or refractory multiple myeloma

Plex Pharmaceuticals presents dual FKBP12/FKBP52 inhibitors

New Tec family kinase inhibitors synthesized at GB005

FDA approves Zulresso for postpartum depression

BioTheryX patents IL-1beta, IL-6, IL-2 and TNF-alpha production inhibitors

The University of Kansas identifies new endoplasmin inhibitors

Merck KGaA and Pfizer discontinue JAVELIN Ovarian PARP 100 study of avelumab

Altimmune reports phase II extension study findings for NasoVAX intranasal influenza vaccine

Tesaro announces data from GARNET study of dostarlimab in endometrial cancer

Studies with cordycepin point to polyadenylation as a target for treating osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.